Literature DB >> 15451522

Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting.

Leila Nobs1, Franz Buchegger, Robert Gurny, Eric Allémann.   

Abstract

In this study, NeutrAvidin was covalently bound to the surface of poly(DL-lactic acid) (PLA) nanoparticles, with the aim of attaching targeting compounds, such as proteins, to their surface. Sulfhydryl groups were first introduced on the surface of PLA nanoparticles through a carbodiimide reaction. NeutrAvidin was then bound to the thiolated nanoparticles via a bifunctional cross-linker, which offers two binding sites, one for primary amine groups and one for thiol functions. The amount of sulfhydryl groups obtained on the surface of the nanoparticles was determined. The NeutrAvidin -labeled nanoparticles were evaluated with respect to particle size, protein concentration and biotin binding capacity. The concentration of thiol functions on the surface of nanoparticles was 105 +/- 15 mmol/mol PLA. The quantification of NeutrAvidin coupled to the nanoparticles revealed that a significant amount of the protein was covalently bound to the nanoparticles. The concentration of NeutrAvidin bound to the nanoparticles could be controlled by varying the amount of protein during the coupling reaction. The maximum concentration of NeutrAvidin attached to the particles was 6 mmol per mol of PLA. The specific activity of NeutrAvidin bound to the nanoparticles was also evaluated and results revealed that the protein maintained the capacity to bind biotin. The activity of the NAR-labeled nanoparticles was lower than expected, due to the undesired aggregation of the native NeutrAvidin. Altogether, the results suggest that other proteins, such as antibodies could be coupled to the nanoparticles for active targeting. Furthermore, PLA nanoparticles bearing NeutrAvidin are interesting candidates for active targeting with biotinylated antibodies using the biotin-avidin interaction in a two step procedure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451522     DOI: 10.1016/j.ejpb.2004.04.006

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  15 in total

Review 1.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

2.  Immunocolloidal targeting of the endocytotic siglec-7 receptor using peripheral attachment of siglec-7 antibodies to poly(lactide-co-glycolide) nanoparticles.

Authors:  Christopher J Scott; Waleed M Marouf; Derek J Quinn; Richard J Buick; Selinda J Orr; Ryan F Donnelly; Paul A McCarron
Journal:  Pharm Res       Date:  2007-08-03       Impact factor: 4.200

Review 3.  Methods for the preparation and manufacture of polymeric nanoparticles.

Authors:  Christine Vauthier; Kawthar Bouchemal
Journal:  Pharm Res       Date:  2008-12-24       Impact factor: 4.200

Review 4.  Applications of orthogonal "click" chemistries in the synthesis of functional soft materials.

Authors:  Rhiannon K Iha; Karen L Wooley; Andreas M Nyström; Daniel J Burke; Matthew J Kade; Craig J Hawker
Journal:  Chem Rev       Date:  2009-11       Impact factor: 60.622

5.  A novel approach for targeted delivery to motoneurons using cholera toxin-B modified protocells.

Authors:  Maria A Gonzalez Porras; Paul N Durfee; Ashley M Gregory; Gary C Sieck; C Jeffrey Brinker; Carlos B Mantilla
Journal:  J Neurosci Methods       Date:  2016-09-15       Impact factor: 2.390

6.  Tetanus toxin C fragment-conjugated nanoparticles for targeted drug delivery to neurons.

Authors:  Seth A Townsend; Gilad D Evrony; Frank X Gu; Martin P Schulz; Robert H Brown; Robert Langer
Journal:  Biomaterials       Date:  2007-09-14       Impact factor: 12.479

7.  Targeted binding of PLA microparticles with lipid-PEG-tethered ligands.

Authors:  Wynter J Duncanson; Michael A Figa; Kevin Hallock; Samuel Zalipsky; James A Hamilton; Joyce Y Wong
Journal:  Biomaterials       Date:  2007-08-17       Impact factor: 12.479

Review 8.  Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies.

Authors:  Mohamed I Nounou; Fatema ElAmrawy; Nada Ahmed; Kamilia Abdelraouf; Satyanarayana Goda; Hussaini Syed-Sha-Qhattal
Journal:  Breast Cancer (Auckl)       Date:  2015-09-27

9.  Ligand-modified gene carriers increased uptake in target cells but reduced DNA release and transfection efficiency.

Authors:  Yen Cu; Cathy LeMoëllic; Michael J Caplan; W Mark Saltzman
Journal:  Nanomedicine       Date:  2009-10-02       Impact factor: 5.307

Review 10.  Drug delivery and nanoparticles:applications and hazards.

Authors:  Wim H De Jong; Paul J A Borm
Journal:  Int J Nanomedicine       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.